Form 4: Versant Funds Divest $7.4M in LENZ Therapeutics Stock

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, reported the sale of 188,094 common shares for approximately $7.4 million in late August 2025.

Summary

• Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P., and Versant Vantage II, L.P., along with their general partners, collectively a 10% owner and director of LENZ Therapeutics, reported significant sales of common stock.
• A total of 188,094 shares of common stock were disposed of across multiple transactions between August 22, 2025, and August 26, 2025.
• The sales occurred at weighted average prices ranging from $38.9744 to $40.5899 per share.
• The total proceeds from these sales are estimated to be approximately $7.42 million.
• Following these transactions, Versant Venture Capital VI, L.P. directly holds 1,274,197 shares, Versant Venture Capital VII, L.P. indirectly holds 900,807 shares, and Versant Vantage II, L.P. indirectly holds 842,162 shares.
• The total beneficial ownership by Versant entities after these sales is 3,017,166 shares.

Sentiment

Score: 3

Explanation: The significant insider selling by a 10% owner and director is a negative signal, indicating a potential lack of confidence or a strategic divestment. While not catastrophic, it warrants caution from investors.

Negatives

• Significant insider selling by a 10% owner and director can be interpreted as a lack of confidence in the company's near-term prospects or a strategic portfolio rebalancing away from LENZ Therapeutics.
• The sales occurred over several days, indicating a systematic reduction in exposure rather than a one-off event.
• The average sale prices were in the range of $38.97 to $40.59, which might suggest that the reporting persons believe the current valuation is favorable for divestment.

Risks

• Increased selling pressure on LENZ Therapeutics' stock due to the large volume of shares sold by a major institutional investor.
• Potential negative market sentiment and investor perception, as insider selling by a director and 10% owner often signals concerns about future performance.
• Reduced institutional support for the company's stock, which could impact liquidity and price stability.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company or the reporting persons regarding future performance or strategic direction.

Industry Context

Insider selling by a venture capital firm that is also a significant shareholder and has board representation can be a notable event in the biotechnology sector. Such sales might indicate a strategic exit or a re-evaluation of the investment thesis, potentially signaling a mature investment phase or concerns about future growth prospects, especially if the company is in clinical development or nearing commercialization.

Comparison to Industry Standards

• This Form 4 reports routine insider selling by a venture capital firm. While the volume is significant, it is not uncommon for venture capital funds to gradually divest their holdings in public companies as their investment horizons mature or as part of portfolio management strategies.
• Without specific industry benchmarks for insider selling by venture capital firms in the biotech sector, a direct comparison to specific comparable companies or projects is not feasible based solely on this filing. However, such sales are typically scrutinized by the market for any underlying signals about the company's prospects.

Related Party Transactions

• The transactions involve sales of common stock by Versant Venture Capital VI, L.P. and Versant Venture Capital VII, L.P., which are part of a group of Versant entities that collectively serve as a 10% owner and have director representation on LENZ Therapeutics' board.
• The various Versant entities (Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC) are related parties, and their beneficial ownership is disclosed with cross-references to their general partners and managing members.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect equity-based compensation.
• Customers/Suppliers/Creditors: No direct impact from this type of filing.

Next Steps

• The filing does not explicitly mention future actions, events, or milestones for LENZ Therapeutics or the reporting persons, beyond the standard legal obligation to report further changes in beneficial ownership.

Key Dates

Recommendation

The substantial sale of common stock by a 10% owner and director, Versant Venture Capital, signals a significant reduction in their stake. Such insider selling, especially by a major institutional investor with board representation, is typically viewed negatively by the market. It suggests that the reporting persons may believe the stock is fully valued or that future prospects are less compelling, warranting a cautious 'sell' recommendation for investors to consider reducing their exposure or avoiding the stock until clearer positive catalysts emerge.

Keywords

LENZ Therapeutics, Versant Venture Capital, Form 4, Insider Selling, Beneficial Ownership, Common Stock, Equity Sales, Director Transactions, 10% Owner, Biotechnology